Agios Pharmaceuticals Inc to Discuss Data from ClarIDHy Study Presented at ESMO - Conference Call
שיחת ועידה Agios Pharmaceuticals Inc
Agios Pharmaceuticals Inc Conference call or earnings call will be held on 30/09/2019 via an 800 number (toll-free). During the earnings conference call's session Agios Pharmaceuticals Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact Agios Pharmaceuticals Inc for this information
Schedule a teleconference with QCONF and get 5 free calls with our conference service.
We are a biopharmaceutical company committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic metabolic disorders, or RGDs, which are a subset of orphan genetic metabolic diseases. Metabolism is a complex biological process involving the uptake and assimilation of nutrients in cells to produce energy and facilitate many of the processes required for cellular division and growth. We focus our efforts on using cellular metabolism, an unexploited area of biological research with disruptive potential, as a platform for developing potentially transformative small molecule medicines. Our most advanced cancer product candidates are AG-221 and AG-120, which target mutated isocitrate dehydrogenase 2 and 1, or IDH2 and IDH1, respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a wide range of hematological malignancies and solid tumors.קרא עוד שיחת ועידה